StocksMediumUpdated•Originally published 5 November 2026•Updated 6 November 2026•
1 min read
Keros Therapeutics Reports Surprise Q3 Profit Beating Analyst Estimates
Key Facts
1Keros Therapeutics reported quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of a $0.96 loss per share.
2The current quarter's earnings of $0.7 per share compare to a loss of $0.18 per share reported a year ago.
Keros Therapeutics reported quarterly earnings of $0.7 per share and net income of $14.2 million for the third quarter of 2026. Zacks reported that these results beat the consensus estimate of a $0.96 loss per share, improving from a loss of $0.18 per share recorded in the prior-year period.
The company attributed the profit to milestones achieved under a license agreement with Takeda. KROS closed at $10.83 on November 4, 2026, with the stock trading between a low of $10.8 and a high of $11.22 during that session.